Glysure Presents Successful Clinical Trial Results at ISICEM
OXFORD, England, March 20, 2012 /PRNewswire/ –
GlySure Limited, developer of in-hospital continuous blood glucose monitoring systems,
announced that Dr Krishna Prasad is presenting the results of its Intensive Care Unit
(ICU) Pilot Trial for the first time at the 32nd International Symposium on Intensive Care
and Emergency Medicine (ISICEM) being held in Brussels, Belgium from March 20th – 23rd,
The data show that the optical fluorescence sensor can successfully measure blood
glucose levels with a high degree of accuracy across a wide range of intensive care
patients throughout their length of stay in the ICU.
The pioneering new research results being presented at ISICEM were collected from
critically ill patients during GlySure’s recent pilot ICU clinical trial. It is the first
major clinical milestone for the venture capital backed medical technology company.
GlySure believes its continuous intravascular glucose monitoring system has the potential
to improve outcomes for over 8 million ICU patients annually.
At ISICEM Principal Investigator Dr Krishna Prasad will present the data from eighteen
ICU patients with a broad range of conditions and co-morbidities including cardiac
surgery, cerebral trauma, sepsis, diabetes and hypertension. All of the critically ill
patients were monitored continuously and accurately for blood glucose levels throughout
their length of stay in the ICU – up to 100 hours of continuous monitoring.
“Clinicians have been waiting for a continuous real-time blood glucose monitor to
support implementation of Tight Glycemic Control protocols for much of the past decade,”
said Dr Prasad.
GlySure CEO Chris Jones said: “We are very excited by the results of the pilot ICU
clinical trial and are delighted to be able to share them for the first time at ISICEM. We
are looking forward to beginning our European and US clinical regulatory trials and
bringing this technology to market to support clinicians in realizing the promise of Tight
GlySure’s presentation is entitled ‘Accuracy of a Continuous Intravascular Glucose
Monitor in ICU Patients’.
GlySure has developed a continuous intravascular glucose monitoring system using a
proprietary optical fluorescence sensor to meet the $2B+ worldwide demand for
implementation of Tight Glycemic Control (TGC) in the hospital Intensive Care Unit (ICU).
GlySure was founded in 2006 and is based in Abingdon, Oxfordshire, England.
Company Contact: Chris Jones, CEO, GlySure. Tel: +44(0)1235-462-870.
Media Contact: Kara Della Vecchia, KDV Communications, Inc. Tel: +1-508-314-3127.
SOURCE GlySure Limited